Introduction
============

Nanotechnology is an emerging field of science with immense scope in the disciplines of electronics, nanomedicine, aeronautics, biomaterials and energy, cosmetics, and food.[@b1-ijn-8-3187] The nanoparticles of metals like platinum, silver, and gold are widely applicable in diagnostic sensors, as antimicrobials, and as agents in drug and gene delivery.[@b2-ijn-8-3187] Currently, there is a growing demand for the devising of environmentally agreeable protocols for the synthesis of nanomaterials that would avoid the hazardous byproducts associated with current physicochemical processes.[@b3-ijn-8-3187],[@b4-ijn-8-3187]

A striking opportunity of green nanotechnology is to utilize microbial resources for the fabrication of nanoparticles. In the recent past, nanoparticles have been synthesized using various fungi,[@b5-ijn-8-3187]--[@b8-ijn-8-3187] bacteria,[@b9-ijn-8-3187],[@b10-ijn-8-3187] and plants.[@b4-ijn-8-3187],[@b11-ijn-8-3187] Bacteria like *Bacillus licheniformis*, *Staphylococcus aureus*, and *Pseudomonas stutzeri* and fungi like *Fusarium semitactum, Fusarium oxysporum, Aspergillus* sp., *Aspergillus flavus*, and *Aspergillus fumigatus* have been reported to synthesize silver, gold, platinum, and palladium nanoparticles.[@b5-ijn-8-3187]--[@b10-ijn-8-3187],[@b12-ijn-8-3187]--[@b15-ijn-8-3187] Compared with chemical and physical methods, biological synthesis of nanoparticles has proved to be free of any limitations associated with production of hazardous byproducts, and it is simple and cost effective in nature.[@b16-ijn-8-3187],[@b17-ijn-8-3187] Microbiological synthesis can take place either intracellularly[@b7-ijn-8-3187],[@b18-ijn-8-3187] or extracellularly.[@b5-ijn-8-3187],[@b6-ijn-8-3187],[@b8-ijn-8-3187],[@b13-ijn-8-3187],[@b15-ijn-8-3187] The mechanism underlying the synthesis of silver nanoparticles (AgNPs) by fungi can also be predicted; biosynthesis is basically associated with the reducing mechanism of the cellular components. In this reference involvement, the specific position of reductase enzymes was typically cited.[@b5-ijn-8-3187],[@b14-ijn-8-3187] The silver ions were subsequently reduced to AgNPs by enzymes present at the fungal cell surfaces.[@b12-ijn-8-3187],[@b13-ijn-8-3187],[@b19-ijn-8-3187] The reduction process was also facilitated by certain extracellular enzymes like naphthoquinones and anthraquinones. For instance, extracellularly, *F. oxysporum*-mediated nicotinamide adenine dinucleotide phosphate-dependent nitrate reductase and a shuttle quinone were accountable for nanoparticle synthesis.[@b5-ijn-8-3187]

The growing resistance of pathogenic bacterial strains to traditional antibacterial treatments has encouraged alternate strategies to control infections.[@b20-ijn-8-3187] During the past decade, a great potential in nanomedicine has been realized due to effectiveness of various nanoconjugates against pathogenic microbes. One approach to countering bacterial drug resistance is the application of metal composites, especially at nano scale, to control bacterial infections. Several enzymes and mutations in genetic sequences may impede multidrug resistance mechanisms by changing the medicine efflux from the cells, which thereby decreases the vulnerability of bacteria to antibacterial agents.[@b21-ijn-8-3187] Therefore, scientists are developing new ways to control resistant pathogens. Advancement in nanotechnology has prompted microbiologists to apply metal nanoparticles as an effective way to control certain pathogenic microbes involved in infectious diseases.[@b7-ijn-8-3187],[@b10-ijn-8-3187],[@b17-ijn-8-3187],[@b22-ijn-8-3187]--[@b24-ijn-8-3187]

Metal nanoparticles of silver, copper, and gold have been found to be active against certain pathogenic bacteria and fungi.[@b23-ijn-8-3187]--[@b31-ijn-8-3187] Comparatively, AgNPs have been intensely studied owing to their distinct properties such as conductivity, chemical stability, catalytic activity, nonlinear optical behavior, and bactericidal activity.[@b23-ijn-8-3187],[@b24-ijn-8-3187],[@b28-ijn-8-3187],[@b32-ijn-8-3187] These properties make them suitable for use as a microbial disinfectant in catheters[@b33-ijn-8-3187] and medical textiles.[@b34-ijn-8-3187] The production of AgNPs is relatively inexpensive, and the addition of these particles into goods such as plastics, clothing, creams, and soaps increase their market value.[@b31-ijn-8-3187] New classes of compounds that include nanoparticle--antibiotic conjugates are undergoing clinical evaluations.[@b20-ijn-8-3187],[@b22-ijn-8-3187],[@b23-ijn-8-3187],[@b26-ijn-8-3187],[@b32-ijn-8-3187],[@b35-ijn-8-3187],[@b36-ijn-8-3187] The combination of antibiotics and metal nanoparticles could increase the antibiotics' efficacy against resistant pathogens.[@b35-ijn-8-3187],[@b36-ijn-8-3187] Moreover, nanoparticle-- antibiotic conjugates lower the amount of both agents in the dosage, which reduces noxiousness and increases antimicrobial properties. These conjugates were effective against resistant bacteria. Additionally, due to this conjugation, the concentrations of antibiotics were increased at the place of antibiotic--microbe contact and thus expedited the binding between microbes and antibiotics.[@b22-ijn-8-3187]

The present research was carried out in response to the significance of biological synthesis of nanoparticles and the implications of their use in controlling pathogenic microbes. AgNP synthesis was evaluated utilizing a fungal strain of *A. flavus*; these nanoparticles were tested for their antibacterial efficacy individually and in combination with various conventional antibiotics against eight different multidrug-resistant bacterial isolates.

Materials and methods
=====================

Microorganisms
--------------

The fungal species *A. flavus* (nonaflatoxin-producing strain, as described by Abbas et al[@b37-ijn-8-3187]) used for the synthesis of nanoparticles, was obtained from the Microbiology Research Laboratory at Quaid-i-Azam University, Islamabad, Pakistan. It was maintained on potato-dextrose agar slants. Stock cultures of the fungus were refreshed by subculturing every 15 days.

Pure cultures of eight different bacterial isolates were also obtained from the Microbiology Research Laboratory at Quaid-i-Azam University; these were previously isolated at the Pakistan Institute of Medical Sciences, Islamabad, Pakistan. Among these multidrug-resistant bacterial strains, *Escherichia coli*, *Pseudomonas aeruginosa*, and *Enterococcus faecalis* were resistant to trimethoprim, vancomycin, and ciprofloxacin; *S. aureus* was resistant to trimethoprim and vancomycin; and *Micrococus luteus* was resistant to trimethoprim, gentamycin, and vancomycin. *Acinetobacter baumanii* was found to be resistant to imipenem, trimethoprim, gentamycin, and vancomycin, and *Klebsiella pneumoniae* and *Bacillus* spp. were resistant to trimethoprim. Stock cultures were refreshed by subculturing every 15 days on nutrient agar plates and were maintained at 4°C.

Cultivation of fungal biomass
-----------------------------

The mycogenesis of AgNPs was performed using *A. flavus*. The fungal biomass was cultivated aerobically in a liquid medium containing malt extract 0.3 g/100 mL, glucose 1.0 g/100 mL, yeast extract 0.3 g/100 mL, and peptone 0.5 g/100 mL. The pH of the medium was initially adjusted to 5.8. The fungal culture was inoculated and then grown at 28°C in an orbital shaker at 150 rpm. After 96 hours, the fungal biomass was removed by filtration using Whatman filter paper no 1. The fungal cultural filtrate was later used for nanoparticle synthesis.

Assay for the synthesis of nanoparticles
----------------------------------------

About 200 mL of mycelia-free fungal cultural filtrate containing 0.1 M precursor salt AgNO~3~ was taken in a 500 mL Erlenmeyer flask. The flask was incubated in a dark condition at 28°C on a shaker at 150 rpm for 96 hours. Positive control (culture filtrate without silver salt) and negative control (only AgNO~3~ solution) were also run along with the experimental flasks, following the method of Bhainsa and D'Souza.[@b8-ijn-8-3187]

Characterization of nanoparticles by X-ray diffraction and transmission electron microscopy
-------------------------------------------------------------------------------------------

During the assay, approximately 1 mL of sample was withdrawn from the reaction mixture at 0 hours, 2 hours, 4 hours, 6 hours, 24 hours, 48 hours, 72 hours, and 96 hours. The absorbance of the sample was noticed at 200--800 nm wavelengths by ultraviolet-visible spectrophotometer (Agilent 8453 UV-Vis, Agilent Technologies, Santa Clara, CA, USA). Colloidal suspension from the reaction mixture containing silver was concentrated using ultracentrifugation (centrifuge Model H-251, Kokusan Co, Ltd, Tokyo, Japan) at 12,000 rpm for 20 minutes. After concentrating, the silver powder was thoroughly washed three times by pure ethanol and then by sterile deionized water in order to get clean nanoparticles. The nanoparticles were microcentrifuged (Microfuge® 18 Centrifuge, Beckman Coulter, Inc, Brea, CA, USA). Finally, the supernatant was removed and the nanoparticles were dried in an oven overnight; hence, the AgNPs were obtained in powder form.

Drop-coated films of dried sample containing nanoparticles on silica were subjected to X-ray diffraction (XRD) analysis (X'pert PRO XRD, PANalytical BV, Almelo, The Netherlands) operating in transmission mode, at 30 kV, 20 mA with Cu Kα radiation. The AgNPs film was created on carbon-coated copper transmission electron microscopy (TEM) grids and examined by TEM (JEM-1010, JEOL Ltd, Tokyo, Japan) at an accelerating voltage of 80 kV.

Preparation of AgNP suspension
------------------------------

An AgNP suspension of 100 ppm was prepared by dissolving 0.1 mg of biologically synthesized AgNPs in 1 mL autoclaved deionized water. The suspension was sonicated for 20 minutes to avoid deposition of AgNPs.

Antibiotics
-----------

Antibiotics were selected from five groups having a different mode of action, including imipenem (carbapenem), trimethoprim (sulfonamide), gentamycin (aminoglycoside), vancomycin (glycopeptide), and ciprofloxacin (quinolone).

Bacterial susceptibility to antibiotics and AgNPs using the Kirby--Bauer disk-diffusion method
----------------------------------------------------------------------------------------------

A disk-diffusion scheme was utilized to assess the antibacterial potential of antibiotics, biologically synthesized AgNPs, and their conjugates against eight different bacteria on Mueller--Hinton agar plates (Becton, Dickinson and Company, Franklin Lakes, NJ, USA).[@b38-ijn-8-3187] The inoculum of each bacterium was developed by growing the organism overnight in Muller-- Hinton liquid medium on a shaker incubator (200 rpm) at 37°C. Turbidity of the culture was maintained by comparing with 0.5% McFarland standard by diluting with 0.9% NaCl solution. Muller--Hinton agar plates were seeded with 1 mL of inoculum of the test bacterial culture to achieve 10^6^ CFU/mL. A lawn of the test organism was made on autoclaved Muller-- Hinton agar plate using sterile swabs. Plates were allowed to set and then nanoparticle-laden, air-dried sterile discs were placed using sterile forceps. Also, for determining synergistic effects, each standard antibiotic disc was impregnated with 30 μL of metallic nanoparticles (100 ppm). Plates were labeled carefully and incubated at 37°C for 24 hours to check the activity. Antibacterial activity was expressed as the diameter of the zone of inhibition, measured in millimeters. The assays were implemented in triplicate. Mean values for inhibition zones are presented in [Table 1](#t1-ijn-8-3187){ref-type="table"}.

Results
=======

Initially, the extracellular synthesis of AgNPs was observed during incubation of reaction mixture containing culture filtrate of *A. flavus* and silver salt at 30°C for 96 hours. The reaction mixture showed a gradual change in coloration from yellow to dark brown ([Figure 1A](#f1-ijn-8-3187){ref-type="fig"}). This change in coloration was not observed in the case of the control flasks ([Figure 1B](#f1-ijn-8-3187){ref-type="fig"} and [C](#f1-ijn-8-3187){ref-type="fig"}). During incubation, the ultraviolet-visible spectros-copy of the reaction mixture showed spectra of increasing intensity (range, 350--600 nm); major peaks were centered around 400--470 nm ([Figure 2](#f2-ijn-8-3187){ref-type="fig"}). The gradual increase in peak areas/absorbance with time was significantly correlated with change in color of the reaction mixture, indicating nanoparticle synthesis.

XRD and Debye--Scherrer analysis of the drop-coated film of dried sample (reaction mixture) revealed the crystalline nature of nanoparticles ([Figure 3](#f3-ijn-8-3187){ref-type="fig"}). XRD patterns showed four major peaks in the entire spectrum of 2*θ* value extending from 20--80 degrees. The mean size of the crystallites was 13--26 nm and the size of the silver nanocrystallites was 21 nm as assessed from the full width at half maximum of the peaks via the Debye-- Scherrer formulae. TEM micrographs showed nanoparticles with various shapes; however, most were spherical. The size of the particles ranged from 5--30 nm ([Figure 4](#f4-ijn-8-3187){ref-type="fig"}).

Antimicrobial activities
------------------------

The efficacy of antibiotics, mycogenized nanoparticles, and their combinations in terms of zones of inhibition (mm) was measured against eight different bacteria ([Table 1](#t1-ijn-8-3187){ref-type="table"}). The decreasing order of the average antibacterial activity of antibiotics, AgNPs, and their conjugates against bacterial group was observed to be ciprofloxacin + AgNP \> imipenem + AgNP \> gentamycin + AgNP \> vancomycin + AgNP \> AgNP \> imipenem \> trimethoprim + AgNP \> ciprofloxacin \> gentamycin \> vancomycin \> trimethoprim. The average antibacterial activity of the various antibiotics against bacterial group ranged from 0.00--13.66 mm (zone of inhibition). Specific antibiotic activities were maximum with: imipenem against *S. aureus* (23 mm)*, K. pneumoniae* (21 mm)*, Bacillus* spp. (21 mm), and *E. coli* (20 mm); ciprofloxacin against *S. aureus* (28 mm)*, Bacillus* spp. (23 mm), and *K. pneumoniae* (22 mm); and gentamycin against *K. pneumoniae* (22 mm) and *Bacillus* spp. (21 mm). All the bacteria except *Bacillus* spp. and *K. pneumoniae* were resistant to vancomycin. Similarly, trimethoprim showed no activity against any of the bacterial species.

In the case of AgNPs, mild bactericidal activities were observed in terms of zone of inhibition ranging from 14--16 mm (average, 14.75 mm) against bacterial group. Combinations of antibiotics and nanoparticles resulted in average fold-area increases in antibacterial activity (zone of inhibition) of 0.2--4.4 for imipenem + AgNP, 3.0--6.1 for trimethoprim + AgNP, 0.3--7.0 for gentamycin + AgNP, 0.3-- 7.0 for vancomycin + AgNP, and 0.1--5.3 for ciprofloxacin + AgNP against bacterial group. Typically, maximum zone(s) of inhibition were observed for *S. aureus* and *Bacillus* spp. with imipenem + AgNP (25 mm), *E. faecalis* with trimethoprim + AgNP (16 mm), *K. pneumoniae* with gentamycin + AgNP (25 mm), and *Bacillus* spp. with vancomycin + AgNP (19 mm) and with ciprofloxacin + AgNP (38 mm).

The tested microbes showed susceptibility in the range of 14--25 mm for imipenem + AgNP conjugate. Trimethoprim + AgNP conjugate exhibited bactericidal activity ranging from 12--16 mm, much better than conventional trimethoprim, which showed no activity against any of the microbes. Gentamycin impregnated with nanoparticles exhibited an efficacy range from 12--25 mm. All the microbes were resistant to vancomycin except *K. pneumoniae* and *Bacillus* spp., which showed efficacy around 16 mm; when vancomycin-infused nanoparticles were used, a 13--19 mm range was obtained. Ciprofloxacin + AgNP conjugate showed efficacy against the entire tested microbial community in the 14--38 mm range. Overall, antibacterial combinations of ciprofloxacin and imipenem impregnated with AgNPs showed the maximum efficacy (23 mm and 21 mm, respectively) against the entire tested bacterial community; gentamycin, vancomycin, and trimethoprim infused with AgNPs exhibited efficacies of 19 mm, 16 mm, and 14 mm against bacterial group. The representative zones of inhibition are shown in [Figure 5](#f5-ijn-8-3187){ref-type="fig"}.

Discussion
==========

The scope of the present study was based upon exploring the capabilities of fungal strain *A. flavus* to synthesize AgNPs along with their biomedical application in controlling infectious bacteria. The fungal isolate showed a great deal of capability towards synthesizing AgNPs. In addition, these nanoparticles alone and also in conjugation with various antibiotics proved to be effective in controlling resistant bacteria.

Change in color of the reaction mixture containing salt of Ag and fungal extract (medium) proved to be the first indication of nanoparticle synthesis.[@b15-ijn-8-3187] When the reaction mixture was incubated under dark conditions, the color of the liquid mixture changed from light yellowish brown to dark brown, and than black, subsequently, after 96 hours of reaction. ([Figure 1](#f1-ijn-8-3187){ref-type="fig"}). This change in color of extracellular medium was previously linked with the formation of AgNPs and depicts the excitation of surface plasmon vibrations in the nanoparticles.[@b39-ijn-8-3187],[@b40-ijn-8-3187] The change in color intensity (absorbance) was also monitored through ultraviolet-visible spectroscopy. Peaks of the reaction mixture were obtained around 420 nm ([Figure 2](#f2-ijn-8-3187){ref-type="fig"}). It was reported that the reduction of Ag^+^ to atomic silver Ag^o^ corresponds to absorption at 420 nm.[@b5-ijn-8-3187],[@b6-ijn-8-3187],[@b8-ijn-8-3187] Synthesis of AgNP was previously linked with release of functional proteins in reaction mixture by *F. oxysporum*, which might have helped reduction of the metal ions into nanoparticles.[@b5-ijn-8-3187]

Various reports have provided evidence of extracellular generation of AgNPs by XRD and TEM images.[@b5-ijn-8-3187]--[@b15-ijn-8-3187] Based upon these analytical techniques, extracellular biosynthesis of AgNPs varied from 10--100 nm by *Aspergillus niger*,[@b15-ijn-8-3187] 5--25 nm by *A. fumigatus*,[@b8-ijn-8-3187] and 8--17 nm by *A. flavus* under shaking conditions (150--200 rpm) at 25°C--30°C.[@b13-ijn-8-3187],[@b14-ijn-8-3187] Similar findings were made in the present study through XRD and TEM, which revealed nanoparticles sized 13--26 nm and 5--30 nm, respectively, by *A. flavus* under shaking conditions (150 rpm) at 30°C. Thus, different *Aspergillus* species were found to be quite capable of synthesizing AgNPs under agitated conditions and specific growth temperatures.

AgNPs have been reported to be an effective bactericidal agent.[@b23-ijn-8-3187],[@b25-ijn-8-3187],[@b30-ijn-8-3187],[@b41-ijn-8-3187]--[@b43-ijn-8-3187] All of the selected clinical bacterial isolates exhibited resistance against conventional sulfonamide (trimethoprim) and glycopeptide (vancomycin) antibiotics. A synergistic effect of antibiotics (imipenem, gentamycin, vancomycin, and ciprofloxacin) in conjugation with biologically synthesized AgNPs increased the susceptibility among the tested bacteria from 20%--35%. The combined effect of AgNPs and antibiotics like imipenem, gentamycin, and ciprofloxacin was notably exhibited against *E. coli, S. aureus, P. aeruginosa, K. pneumoniae, Bacillus* spp., and *M. luteus*. These results are in line with the findings of Birla et al,[@b41-ijn-8-3187] who mentioned increasing efficacies (percentage) of antibiotics like vancomycin, gentamycin, streptomycin, ampicillin, and kanamycin when used in combination with AgNPs against *P. aeruginosa, S. aureus*, and *E. coli*. In a similar study,[@b35-ijn-8-3187] the antimicrobial activities of biologically synthesized AgNPs were assessed with commercially available antibiotics against G-- and G+ bacteria. The antibacterial activities of ampicillin, chloramphenicol, erythromycin, and kanamycin were augmented in the presence of AgNPs. However, highest synergistic effect was observed with ampicillin. Higher dosage for both the AgNPs (0--40 μg/mL) and amoxicillin (0--0.5 mg/mL) exhibited higher antibacterial effects against *E. coli* in Luria--Bertani medium. When amoxicillin impregnated with AgNPs was applied, a superior antibacterial efficiency on *E. coli* cells was obtained than when they were applied separately. Moreover, through dynamic trials/set of experiments it was also found that when this combination was used, the bacterial growth showed reduced and deferred exponential and stationary phases. The higher the number of nanoparticles, the more the bactericidal activity.[@b36-ijn-8-3187]

The mechanism of action of AgNPs is still not well defined. Many proposed mechanisms about antibacterial effect of silver ions have been presented by researchers.[@b23-ijn-8-3187],[@b25-ijn-8-3187],[@b29-ijn-8-3187],[@b30-ijn-8-3187],[@b35-ijn-8-3187],[@b36-ijn-8-3187],[@b43-ijn-8-3187]--[@b45-ijn-8-3187] It was hypothesized that nanoparticles form a complex with ampicillin and disrupt peptidoglycan in the cell wall.[@b35-ijn-8-3187] Being positively charged, they attack negative charges of transmembrane proteins and can destroy the cell membrane and block the transport channels.[@b44-ijn-8-3187] It might be possible that they penetrate inside the bacteria and disrupt cellular activities like transportation, protein synthesis, and nucleic acid functioning.[@b45-ijn-8-3187] Likewise, imipenem in combination with positively charged AgNPs both inhibited and disrupted cell-wall synthesis.[@b26-ijn-8-3187] It has also been proposed that silver ions penetrate the cell, intercalate themselves between pyrimidine and purine, and denature the DNA molecule.[@b23-ijn-8-3187] The antibiotics ciprofloxacin and imipenem in combination with these AgNPs were found to be most effective in inhibiting bacteria: if bacteria develops resistance to one of them, the other bactericidal agent would kill the bacteria. In synergism, the bactericidal effect is enhanced by interaction between active groups like hydroxyl and amino groups present in these antibiotics with AgNPs by chelation. As a result, antibiotic--AgNP conjugate is formed in which an AgNP core is surrounded by antibiotic molecules. Thus, the antimicrobial concentration is increased at the focal site, which leads to increased destruction of bacteria.[@b36-ijn-8-3187] More studies need to be conducted to find out the exact mechanism of action to develop a novel antimicrobial drug against multidrug-resistant bacteria.

Conclusion
==========

In this study, *A. flavus* was found to be an effective biological tool for the extracellular biosynthesis of stable AgNPs. The antibacterial activity of imipenem, gentamycin, vancomycin, and ciprofloxacin was augmented when impregnated with AgNPs. On the basis of the results from this study, we can deduce that biologically synthesized AgNPs may function by binding to thiol (SH) groups of membrane proteins, enzymes, and phosphate groups of DNA, and can be efficiently used as antimicrobial agents.
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![Extracellular synthesis of AgNPs at the beginning of the reaction and after 96 hours (completion of reaction).\
**Notes:** (**A**) Culture filtrate: *Aspergillus flavus* with AgNO~3~ solution (0.1 M). (**B**) Positive control: filtrate without silver salt. (**C**) Negative control: sterile deionized water with only AgNO~3~ solution.\
**Abbreviation:** AgNPs, silver nanoparticles.](ijn-8-3187Fig1){#f1-ijn-8-3187}

![Ultraviolet-visible spectra of aqueous medium containing cell free culture filtrate and silver salt (0.1 M) and of controls over time.](ijn-8-3187Fig2){#f2-ijn-8-3187}

![X-ray diffraction pattern of nanoparticle film on copper surface obtained from culture filtrate of *Aspergillus flavus*.](ijn-8-3187Fig3){#f3-ijn-8-3187}

![Transmission electron micrograph of AgNPs produced by culture filtrate of *Aspergillus flavus*.\
**Abbreviation:** AgNPs, silver nanoparticles.](ijn-8-3187Fig4){#f4-ijn-8-3187}

![Zones of inhibition of standard antibiotics and AgNPs against multidrug-resistant microorganisms.\
**Notes:** (**A**) *Bacillus*; (**B**) *M. luteus*; (**C**) *S. aureus*; (**D**) *E. faecalis*; (**E**) *E. coli*; (**F**) *P. aeruginosa*; (**G**) *A. baumanii*; (**H**) *K. pneumoniae*.\
**Abbreviation:** AgNPs, silver nanoparticles.](ijn-8-3187Fig5){#f5-ijn-8-3187}

###### 

Combined and individual efficacy of antibiotics and AgNPs against selected bacteria

                                                                                                             Bacterial isolates                                                                                                                                                                                                                                                                                                                                                                      
  ---------------------------------------------------------------------------------------------------------- --------------------------------------------- --------------------------------------------- --------------------------------------------- --------------------------------------------- --------------------------------------------- --------------------------------------------- --------------------------------------------- --------------------------------------------- ------- -----
  **Zone of inhibition (mm) of various antibiotic combinations with AgNPs (average ± standard deviation)**                                                                                                                                                                                                                                                                                                                                                                                           
  Imipenem (a)                                                                                               20 ± 1                                        23 ± 1                                        18± 1                                         12 ± 0.6                                      16 ±0.6                                       0[†](#tfn2-ijn-8-3187){ref-type="table-fn"}   21 ± 1                                        21 ± 1.7                                      13.66   CDE
   AgNP                                                                                                      15 ± 1.5                                      16±2                                          14± 1                                         14± 1.5                                       15± 1.5                                       15± 1                                         14 ±0.6                                       15± 1.5                                       14.75   CD
   Imipenem + AgNP (b)                                                                                       22 ±2                                         25 ±2                                         20 ± 0.6                                      20 ± 0.6                                      20 ± 0.6                                      14 ±0.6                                       24 ± 1.2                                      25 ± 0.6                                      21.3    A
  Increase in fold area[‡](#tfn3-ijn-8-3187){ref-type="table-fn"}                                            0.21                                          0.18                                          0.23                                          1.78                                          0.56                                          4.44                                          0.31                                          0.42                                                  
   Trimethoprim (a) (2.5 μg)                                                                                 0[†](#tfn2-ijn-8-3187){ref-type="table-fn"}   0[†](#tfn2-ijn-8-3187){ref-type="table-fn"}   0[†](#tfn2-ijn-8-3187){ref-type="table-fn"}   0[†](#tfn2-ijn-8-3187){ref-type="table-fn"}   0[†](#tfn2-ijn-8-3187){ref-type="table-fn"}   0[†](#tfn2-ijn-8-3187){ref-type="table-fn"}   0[†](#tfn2-ijn-8-3187){ref-type="table-fn"}   0[†](#tfn2-ijn-8-3187){ref-type="table-fn"}   0       G
   AgNP                                                                                                      15 ± 1.5                                      16±2                                          14± 1                                         14± 1.5                                       15± 1.5                                       15± 1                                         14 ±0.6                                       15± 1.5                                       14.75   CD
   Trimethoprim + AgNP (b)                                                                                   13± 1                                         15±2                                          13± 1                                         13 ± 0.6                                      16 ±0.6                                       13 ± 0.6                                      12± 1                                         13 ± 0.6                                      13.5    CDE
  Increase in fold area[‡](#tfn3-ijn-8-3187){ref-type="table-fn"}                                            3.69                                          5.25                                          3.69                                          3.69                                          6.1 1                                         3.69                                          3.00                                          3.69                                                  
   Gentamycin (a) ( 10 μg)                                                                                   9± 1.2                                        15± 1.5                                       0[†](#tfn3-ijn-8-3187){ref-type="table-fn"}   14± 1.5                                       8 ±0.6                                        0[†](#tfn2-ijn-8-3187){ref-type="table-fn"}   22 ± 0.6                                      21 ± 1                                        11.13   E
   AgNP                                                                                                      15 ± 1.5                                      16±2                                          14± 1                                         14± 1.5                                       15± 1.5                                       15± 1                                         14 ±0.6                                       15± 1.5                                       14.75   CD
   Gentamycin + AgNP (b)                                                                                     12± 1                                         21 ±2                                         17+2                                          18± 1                                         15 ±0.6                                       16± 1                                         25 ± 1                                        24 ± 0.6                                      18.5    B
  Increase in fold area[‡](#tfn3-ijn-8-3187){ref-type="table-fn"}                                            0.78                                          0.96                                          7.02                                          0.65                                          2.51                                          6.1 1                                         0.29                                          0.31                                                  
   Vancomycin (a) (30 μg)                                                                                    0[†](#tfn2-ijn-8-3187){ref-type="table-fn"}   0[†](#tfn2-ijn-8-3187){ref-type="table-fn"}   0[†](#tfn2-ijn-8-3187){ref-type="table-fn"}   0[†](#tfn2-ijn-8-3187){ref-type="table-fn"}   0[†](#tfn2-ijn-8-3187){ref-type="table-fn"}   0[†](#tfn2-ijn-8-3187){ref-type="table-fn"}   16± 1                                         16 ±0.6                                       4.00    F
   AgNP                                                                                                      15 ± 1.5                                      16±2                                          14± 1                                         14± 1.5                                       15± 1.5                                       15± 1                                         14 ±0.6                                       15± 1.5                                       14.75   CD
   Vancomycin + AgNP (b)                                                                                     13±2                                          14±2                                          17+2                                          17± 1                                         13 ±0.6                                       13 ± 0.6                                      18 ±0.6                                       19± 1                                         15.5    C
  Increase in fold area[‡](#tfn3-ijn-8-3187){ref-type="table-fn"}                                            3.69                                          4.44                                          7.02                                          7.02                                          3.69                                          3.69                                          0.27                                          0.41                                                  
   Ciprofloxacin (a) (10 μg)                                                                                 0[†](#tfn2-ijn-8-3187){ref-type="table-fn"}   28 ± 0.6                                      19± 1                                         0[†](#tfn2-ijn-8-3187){ref-type="table-fn"}   0[†](#tfn2-ijn-8-3187){ref-type="table-fn"}   8 ±0.6                                        22 ±0                                         23 ± 0.6                                      12.50   DE
   AgNP                                                                                                      15 ± 1.5                                      16±2                                          14± 1                                         14± 1.5                                       15± 1.5                                       15± 1                                         14± 1                                         15± 1.5                                       14.75   CD
   Ciprofloxacin + AgNP (b)                                                                                  14±2                                          29 ± 1                                        21 ± 1                                        15 ± 1.5                                      14± 1                                         18 ±0.6                                       35 ± 1                                        38 ± 0.6                                      23.0    A
  Increase in fold area[‡](#tfn3-ijn-8-3187){ref-type="table-fn"}                                            4.44                                          0.07                                          0.22                                          5.25                                          4.44                                          4.06                                          1.53                                          1.73                                                  
  Rank[\*](#tfn1-ijn-8-3187){ref-type="table-fn"}                                                            CD                                            AB                                            C                                             CD                                            CD                                            D                                             B                                             A                                                     

**Notes:**

Alphabets indicate the rank order; values sharing a common letter do not differ significantly, whereas others differ significantly (*P* \< 0.05). Vertically, ranking associated with antibiotic combinations against bacterial isolates; horizontally, ranking associated with bacterial isolates in terms of sensitivity against antibiotic combinations.

In the absence of bacterial growth inhibition zones, the disc's diameter (6 mm) was used to calculate the fold increases (Birla et al[@b41-ijn-8-3187]);

increase in fold area = (b^2^ − a^2^)/a^2^.

**Abbreviations:** AgNP, silver nanoparticles; *E coli*, *Escherichia coli*; *S. aureus*, *Staphylococcus aureus*; *M. luteus*, *Micrococus luteus*; *P. aeruginosa*, *Pseudomonas aeruginosa*; *E. faecali*, *Enterococcus faecalis*; *A. baumani*, *Acinetobacter baumanii*; *K. pneumoniae*, *Klebsiella pneumoniae*; *Bacillus* spp., *Bacillus species*.
